| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
WAY-117885 does not have a well-defined pharmacological target. It has been catalogued in reagent supplier listings as a tool compound for signaling and kinase research applications. The compound is a small-molecule inhibitor noted for its activity in kinase profiling datasets. The precise mechanism by which WAY-117885 exerts its effects remains an area of active research.
|
|---|---|
| ln Vitro |
In vitro, WAY-117885 is a laboratory reagent used to alter the lifespan of eukaryotes. It is a small-molecule inhibitor noted for its activity in kinase profiling datasets. The compound exhibits interesting properties as a bioactive molecule. However, detailed in vitro activity data are limited in publicly available sources.
|
| ln Vivo |
In vivo, WAY-117885 has been studied for its potential to alter the lifespan of eukaryotic organisms. However, detailed in vivo efficacy data are sparse in the public domain. The precise mechanism by which WAY-117885 exerts its effects remains an area of active research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for WAY-117885 would typically involve kinase profiling to identify its targets. The compound can be screened against a panel of kinases at various concentrations, and kinase activity is measured using luminescent or fluorescence-based assays. Binding to specific kinases can be assessed using surface plasmon resonance or thermal shift assays.
|
| Cell Assay |
In vitro cell-based assays for WAY-117885 involve culturing eukaryotic cells and treating them with the compound to assess effects on cell viability, proliferation, or lifespan-related markers. Cells are treated with WAY-117885 at various concentrations, and cell viability is assessed using MTT or CellTiter-Glo assays. Markers of cellular senescence or stress responses can be measured. Standard cell culture protocols are employed.
|
| Animal Protocol |
In vivo animal studies for WAY-117885 have not been extensively reported. If conducted, such studies might involve model organisms such as yeast, C. elegans, or mice to assess effects on lifespan. WAY-117885 would be administered, and survival curves, healthspan parameters, and biochemical markers would be assessed. No specific data are available from publicly accessible sources.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of WAY-117885 have not been characterized. As a small molecule with a molecular weight of 295.31 and a molecular formula of C13H13NO5S, it is expected to have moderate oral bioavailability. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of WAY-117885 has not been systematically evaluated. As a laboratory reagent and research compound, it is handled with standard laboratory precautions. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| Additional Infomation |
WAY-117885 is a research compound and has not been approved for clinical use. It is a laboratory reagent that has been studied for its potential to alter the lifespan of eukaryotic organisms. WAY-117885 is a small-molecule inhibitor noted for its activity in kinase profiling datasets. It has been catalogued in reagent supplier listings as a tool compound for signaling and kinase research applications. The precise mechanism of action remains an area of active research.
|
| Molecular Formula |
C13H13NO5S
|
|---|---|
| Molecular Weight |
295.309
|
| Exact Mass |
295.051
|
| Elemental Analysis |
C, 52.87; H, 4.44; N, 4.74; O, 27.09; S, 10.86
|
| CAS # |
337494-85-6
|
| PubChem CID |
716043
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.635
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
425
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)S(=O)(=O)N(CC2=CC=CO2)CC(=O)O
|
| InChi Key |
CJROUZFQNICTKL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H13NO5S/c15-13(16)10-14(9-11-5-4-8-19-11)20(17,18)12-6-2-1-3-7-12/h1-8H,9-10H2,(H,15,16)
|
| Chemical Name |
Glycine, N-(2-furanylmethyl)-N-(phenylsulfonyl)-
|
| Synonyms |
WAY-117885; WAY 117885; WAY117885;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3863 mL | 16.9314 mL | 33.8627 mL | |
| 5 mM | 0.6773 mL | 3.3863 mL | 6.7725 mL | |
| 10 mM | 0.3386 mL | 1.6931 mL | 3.3863 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
